Beta Drugs Board Approves AGM, Auditors, and Director Re-appointment
Beta Drugs Limited's Board approved the 21st AGM on September 30th, 2026. Charu Jindal & Co. and V.K. Srivastva & Associates were appointed as Cost and Internal Auditors respectively for FY 2026-27. The statutory auditor was re-appointed for two years, and Mr. Ashutosh Shukla was re-appointed as Whole-Time Director for five years from January 20, 2027.
The re-appointment of key auditors and a Whole-Time Director, along with the scheduling of the AGM, are important corporate governance events that impact the company's operational continuity and compliance. These decisions are crucial for stakeholder confidence and regulatory adherence.
The announcement details routine corporate actions such as board meeting outcomes, AGM scheduling, auditor appointments, and director re-appointments. These are standard procedures and do not indicate a significant positive or negative shift in the company's performance or outlook.
Beta Drugs Limited announced the outcome of its Board Meeting held on September 3rd, 2026. The Board unanimously approved the draft notice for the Annual General Meeting (AGM), which is scheduled to be held on Wednesday, September 30th, 2026, at 10:30 a.m. at the company's registered office.
The book closure for the transfer of members and share transfer books for the 21st AGM will be from Thursday, September 24th, 2026, to Wednesday, September 30th, 2026, inclusive.
Further, the Board approved the Director's Report for the period ended March 31st, 2026. In terms of appointments, Charu Jindal & Co. has been appointed as the Cost Auditor and V.K. Srivastva & Associates as the Internal Auditor for the financial year 2026-27. The company also approved the re-appointment of its statutory auditor for a period of two years from FY 2026-27 to 2027-28, subject to shareholder approval.
Additionally, the Board approved the re-appointment of Mr. Ashutosh Shukla as Whole-Time Director for a period of five years, effective January 20th, 2027, until January 19th, 2032, subject to shareholder approval. The revision of his remuneration was also approved, pending shareholder consent.
A plain-language summary of a public exchange filing by Beta Drugs Limited. Read the original for the full detail.